We pooled together data from two phase I/II trials on transplant-ineligible patients with multiple myeloma receiving upfront carfilzomib cyclophosphamide and
This Phase I/II study was designed to determine the maximum tolerated dose (MTD) of once weekly carfilzomib combined with
The dose of carfilzomib was gradually increased from 36 mg/m2 to 45 mg/m2 to 56 mg/m2
The average time to treatment
1 is a single arm phase II trial of weekly carfilzomib, cyclophosphamide and dexamethasone (wKCd), exploring a convenient immunomodulator (IMiD)-free regimen in relapsed myeloma
The MCRN-003/CCTGMYX
Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible Conclusions
Yeung, Pharm
Lenalidomide plus dexamethasone has been combined with carfilzomib, 2 ixazomib, 3 elotuzumab, 4 and daratumumab
carfilzomib
Some of the information, including information about funding for cancer drugs, does not apply to all patients
They can be used alone or combined with other drugs as a part of treatment
This multicentre, open-label phase 1/2 trial determined safety and efficacy of weekly carfilzomib plus cyclophosphamide-dexamethasone (wKCyd) in newly diagnosed multiple myeloma (NDMM) patients aged ⩾65 years or transplant ineligible
Introduction: Carfilzomib dosed at 56 mg/m 2 twice a week in combination with dexamethasone (Kd) is a standard of care for RRMM after 1-3 prior lines (PL) based on the ENDEAVOR study